The operationalization of
mild cognitive impairment (MCI) led to targeting earlier symptomatic cases of the illness and treatment strategies based less on pathology and more on a chance to halt or slow decline than there would be earlier in the disease.1
With the development of amyloid imaging, MCI due to
AD diagnosis was refined, 2 and early - stage
AD was extended further to include preclinical
AD, 3 wherein a positive amyloid positron emission tomography (PET) scan or diagnostic low levels of cerebrospinal fluid β - amyloid (Aβ) indicated the presence of pathology in
people who were cognitively normal.
About Site - This website was created to offer the most up - to - date Alzheimer's disease (
AD) information to educate family members and caregivers, and provide help for
people with mild memory loss due to
AD.
About Blog This website was created to offer the most up - to - date Alzheimer's disease (
AD) information to educate family members and caregivers, and provide help for
people with mild memory loss due to
AD.